FY2025 EPS Estimates for CEL-SCI Boosted by Zacks Small Cap

CEL-SCI Co. (NYSE:CVM) – Research analysts at Zacks Small Cap boosted their FY2025 earnings estimates for CEL-SCI in a note issued to investors on Monday, February 10th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($0.29) per share for the year, up from their prior estimate of ($0.38). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.38) per share. Zacks Small Cap also issued estimates for CEL-SCI’s FY2026 earnings at ($0.18) EPS.

Separately, StockNews.com began coverage on shares of CEL-SCI in a report on Sunday. They issued a “sell” rating on the stock.

CEL-SCI Stock Up 3.9 %

Shares of CEL-SCI stock opened at $0.37 on Wednesday. CEL-SCI has a 52-week low of $0.33 and a 52-week high of $2.50. The firm’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.81. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The company has a market cap of $27.68 million, a P/E ratio of -0.73 and a beta of 0.69.

Institutional Investors Weigh In On CEL-SCI

Several institutional investors have recently added to or reduced their stakes in CVM. Calton & Associates Inc. acquired a new stake in CEL-SCI in the 3rd quarter worth approximately $50,000. Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI during the third quarter worth $98,000. Finally, Geode Capital Management LLC grew its holdings in shares of CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.